Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?

Severa, Martina; Farina, Cinthia; Salvetti, Marco; Coccia, Eliana M.

doi:10.3389/fimmu.2020.01459

Cited by 17 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to Clementi et al's study, IFN- β -1a could effectively have an inhibitor role in virus-contaminated cells [ 15 ]. Furthermore, it was recommended to use IFN- β -1a therapy to preserve functional B-cell-mediated humoral immunity in MS patients in the COVID-19 era [ 16 ]. As we utilize IFN- β -1a with a brand name of Resigen in the first-line therapy of MS patients, we initiated it in our patient, which resulted in a beneficial outcome [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, it was recommended to use IFN- β -1a therapy to preserve functional B-cell-mediated humoral immunity in MS patients in the COVID-19 era [ 16 ]. As we utilize IFN- β -1a with a brand name of Resigen in the first-line therapy of MS patients, we initiated it in our patient, which resulted in a beneficial outcome [ 16 ]. Despite all these findings, further and strong surveys are necessary to investigate the correlation between MS and SARS-CoV-2 for possible pathophysiology and appropriate management.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Demyelinating Changes Alike to Multiple Sclerosis: A Case Report of Rare Manifestations of COVID-19

Yavari

Raji

Moradi

et al. 2020

Case Reports in Neurological Medicine

View full text Add to dashboard Cite

COVID-19, as a global concern and pivotal issue in the healthcare system, could have various presentations, leading to difficulty in diagnosis and management. Neuroinvasive potency, as claimed by preliminary studies, is a considerable pathogenesis. Serious neurological disorders like multiple sclerosis (MS) were out of the blue to be the first demonstration of COVID-19. This report highlights the representation of MS in a young woman, which resulted in a COVID-19 diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Demyelinating Changes Alike to Multiple Sclerosis: A Case Report of Rare Manifestations of COVID-19

Yavari

Raji

Moradi

et al. 2020

Case Reports in Neurological Medicine

View full text Add to dashboard Cite

show abstract

“…No observed drawbacks were associated with IFN-β administration except lymphopenia. [55,56] Studies regarding the IFN-β antiviral COVID-19 replication are suggested to be effective through activating Janus kinases (JAKs) pathways leading to activated antiviral and antiproliferative actions. [57,58] It was severally reported an increase in COVID-19 neurological manifestations as a drawback of IFN-β administration in infected patients.…”

Section: The Impact Of Immunotherapies In Managing Neurological Manifmentioning

confidence: 99%

“…[57,58] It was severally reported an increase in COVID-19 neurological manifestations as a drawback of IFN-β administration in infected patients. [55][56][57] Remdesivir is a promising nucleoside antiviral analog drug currently used in controlling COVID-19 delirium complications. [59,60] Although Remdesivir has been widely used in COVID-19 treatment protocols, no significant clinical or antiviral effective actions were observed.…”

Section: The Impact Of Immunotherapies In Managing Neurological Manifmentioning

confidence: 99%

Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article

Anwar

2020

Journal of Immunoassay and Immunochemistry

View full text Add to dashboard Cite

In December 2019, an outbreak of pandemic severe respiratory distress syndrome coronavirus disease 2019 (COVID-19) initially occurred in China, has spread the world resulted in serious threats to human public health. Uncommon neurological manifestations with pathophysiological symptoms were observed in infected patients including headache, seizures, and neuroimmunological disorders. Regardless of whether these neurological symptoms are direct or indirect casual infection relationship, this novel viral infection has a relevant impact on the neuroimmune system that requires a neurologist's careful assessment. Recently, the use of immunotherapy has been emerged in fighting against COVID-19 infection despite the uncertain efficiency in managing COVID-19 related disorders or even its proven failure by increasing its severity. Herein, the author is addressing the first approaches in using immunotherapies in controlling COVID-19 viral impact on the brain by highlighting their role in decreasing or increasing infection risks among subjects. This point of view review article supports the use of immunotherapies in managing COVID-19 neurological disorders but in optimal timing and duration to ensure the maximum therapeutic outcome by reducing morbidity and mortality rate. Based on recently published data, the current review article highlights the beneficial effects and drawbacks of using immunotherapies to combat COVID-19 and its neurological symptoms.

show abstract

“… 54 , 55 Through their profile both as a drug for MS and in the context of COVID-19, IFN-β-based therapies are standing out through their safety profile, the speculative positive role in case of infection, and through their potential of non-interference with the efficacy of future SARS-CoV-2 vaccines. 55 , 56 …”

Section: Introductionmentioning

confidence: 99%

Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic

Dumitrescu

Παπαθανασίου

Coclitu

et al. 2021

QJM: An International Journal of Medicine

View full text Add to dashboard Cite

Beta interferons (IFN-β) are pleiotropic cytokines with antiviral properties. They play important roles in the pathogenesis of multiple sclerosis (MS), an incurable immune-mediated disorder of the central nervous system. The clinical expression of MS is heterogeneous, with relapses of neuroinflammation and with disability accrual in considerable part unrelated to the attacks. The injectable recombinant IFN-β preparations are the first approved disease-modifying treatments for MS. They have moderate efficacy in reducing the frequency of relapses, but good long-term cost-efficacy and safety profiles, so are still widely used. They have some tolerability and adherence issues, partly mitigated in recent years by the introduction of a PEGylated formulation and use of ‘smart’ autoinjector devices. Their general impact on long-term disability is modest but could be further improved by developing accurate tools for identifying the patient profile of best responders to IFN-β. Here, we present the IFN-β-based immunomodulatory therapeutic approaches in MS, highlighting their place in the current coronavirus disease (COVID-19) pandemic. The potential role of IFN-β in the treatment of COVID-19 is also briefly discussed.

show abstract

Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?

Cited by 17 publications

References 29 publications

Demyelinating Changes Alike to Multiple Sclerosis: A Case Report of Rare Manifestations of COVID-19

Demyelinating Changes Alike to Multiple Sclerosis: A Case Report of Rare Manifestations of COVID-19

Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article

Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic

Contact Info

Product

Resources

About